WA
SRPT icon

Whipplewood Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Whipplewood Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-59
Closed -$2.49K – 1264
2025
Q1 		$2.49K Buy
59
+20
+51% +$2.1K ﹤0.01% 840
2024
Q4 		$4.74K Buy
+39
New +$4.78K ﹤0.01% 708

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Whipplewood Advisors's SRPT Position: Q2 2025 in Review

Whipplewood Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 59 shares — an estimated $2.49K sold.

Whipplewood Advisors first reported a position in SRPT in Q4 2024 and held it in 2 quarters. The position peaked at $4.74K in Q4 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Whipplewood Advisors reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Whipplewood Advisors sold 59 Sarepta Therapeutics shares in Q2 2025, an estimated $2.49K.
  • Whipplewood Advisors first reported a position in Sarepta Therapeutics in Q4 2024 and held it in 2 quarters.
  • Whipplewood Advisors's Sarepta Therapeutics position peaked at $4.74K in Q4 2024.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Whipplewood Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.